SCHEMBL6777369

SCHEMBL6777369

CC(O)CCCCCCCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 7/20 0.66
TNF P01375 4/20 0.66
USP2 O75604 1/20 0.66
LMNA P02545 1/20 0.66
CYP1A2 P05177 1/20 0.66
TSHR P16473 1/20 0.66
NFKB1 P19838 1/20 0.66
ACHE P22303 1/20 0.66
PDE4A P27815 1/20 0.66
PMP22 Q01453 1/20 0.66
PDE4B Q07343 1/20 0.66
PDE4C Q08493 1/20 0.66
PDE4D Q08499 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
RXFP1 Q9HBX9 1/20 0.66
CHIT1 Q13231 1/20 0.57
CHIA Q9BZP6 1/20 0.57
AKR1B1 P15121 1/20 0.55
GLA P06280 1/20 0.54
BLM P54132 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780935 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL8686678 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL6778207 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL6778919 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL6779520 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL8699282 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL6774460 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL6783783 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL8700060 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2
SCHEMBL6779587 1.00 ADORA2B (0.66) ADORA2BTNFUSP2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693105-B1 USING XANTHINYL DERIVATIVES TO REDUCE TREATMENT INDUCED TOXICITY; INHIBITING CELLULAR SIGNALING THROUGH SECOND MESSENGER PATHWAY; REDUCING CELLULAR LEVEL OF NONARACHI-DONATE PHOSPHATIDIC ACID AND DIACYLGLYCEROL CELL THERAPEUTICS, INC. 2004-02-17 US disclosed
US-6133274-A TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS CELL THERAPEUTICS, INC. (US) 2000-10-17 US disclosed
US-5859017-A PREVENTING OR TREATING ALLERGIES; INHIBITING INTRACELLULAR GENERATION OF PHOSPHATIDIC ACID AND DIACYLGLYCEROL CELL THERAPEUTICS, INC. (US) 1999-01-12 US disclosed
US-5780476-A ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS CELL THERAPEUTICS, INC. (US) 1998-07-14 US disclosed
EP-0669825-A4 HYDROXYL-CONTAINING COMPOUNDS. CELL THERAPEUTICS INC (US) 1996-04-03 EP disclosed
WO-1995026722-A1 METHOD FOR INHIBITING MAST CELL AND BASOPHIL ACTIVATION CELL THERAPEUTICS, INC. (US) 1995-10-12 WO disclosed
EP-0669825-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1995-09-06 EP disclosed
WO-1994011001-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-05-26 WO disclosed